Edward H Myles Insider Trading $AVM AMAG PHARMACEUTICALS, INC.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Edward H Myles.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Edward H Myles. Edward H Myles is Chief Financial Officer in AMAG PHARMACEUTICALS INC. ($AVM) and COO & CFO in AMAG PHARMACEUTICALS, INC. ($AVM) and Vice President of Finance/CFO in PRESSURE BIOSCIENCES INC ($PBIO) and VP of Finance & CFO in PRESSURE BIOSCIENCES INC ($PBIO) and COO & CFO in Ocata Therapeutics, Inc. ($ACTC) and Chief Financial Officer in Scholar Rock Holding Corp ($SRRK) and Director in Scholar Rock Holding Corp ($SRRK).
Edward H Myles in AMAG PHARMACEUTICALS, INC.
Trading Symbol: AVMIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Edward H Myles: COO & CFO, Chief Financial Officer
Holdings: 98,659 shares
Latest Transaction: Mar 12 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Edward H Myles in AMAG PHARMACEUTICALS, INC.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AVM, ACTC, PBIO, SRRK
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 12 2020 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | COO & CFO | Option Exercise | A | 7.27 | 45,000 | 327,150 | 45,000 | |
Mar 12 2020 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | COO & CFO | Grant | A | 0.00 | 30,000 | 0 | 98,659 | 68.7 K to 98.7 K (+43.69 %) |
Mar 04 2020 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | COO & CFO | Payment of Exercise | F | 7.75 | 1,021 | 7,913 | 68,659 | 69.7 K to 68.7 K (-1.47 %) |
Feb 25 2020 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | COO & CFO | Payment of Exercise | F | 8.84 | 1,386 | 12,252 | 77,180 | 78.6 K to 77.2 K (-1.76 %) |
Feb 25 2020 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | COO & CFO | Payment of Exercise | F | 9.50 | 867 | 8,237 | 78,566 | 79.4 K to 78.6 K (-1.09 %) |
Apr 12 2019 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Payment of Exercise | F | 12.47 | 1,964 | 24,491 | 79,433 | 81.4 K to 79.4 K (-2.41 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Option Exercise | A | 15.51 | 25,000 | 387,750 | 25,000 | |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 20,000 | 0 | 82,461 | 62.5 K to 82.5 K (+32.02 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 12,000 | 0 | 62,461 | 50.5 K to 62.5 K (+23.78 %) |
Feb 26 2019 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Payment of Exercise | F | 15.51 | 869 | 13,478 | 50,461 | 51.3 K to 50.5 K (-1.69 %) |
Jul 03 2018 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Payment of Exercise | F | 19.85 | 1,964 | 38,985 | 51,330 | 53.3 K to 51.3 K (-3.69 %) |
Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Option Exercise | A | 21.00 | 24,000 | 504,000 | 24,000 | |
Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Payment of Exercise | F | 21.00 | 854 | 17,934 | 53,294 | 54.1 K to 53.3 K (-1.58 %) |
Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 10,000 | 0 | 54,148 | 44.1 K to 54.1 K (+22.65 %) |
Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 10,000 | 0 | 44,148 | 34.1 K to 44.1 K (+29.28 %) |
May 10 2017 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Payment of Exercise | F | 18.55 | 2,177 | 40,383 | 32,823 | 35 K to 32.8 K (-6.22 %) |
Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Option Exercise | A | 23.75 | 20,000 | 475,000 | 20,000 | |
Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 7,500 | 0 | 35,000 | 27.5 K to 35 K (+27.27 %) |
Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 7,500 | 0 | 27,500 | 20 K to 27.5 K (+37.50 %) |
Apr 11 2016 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Option Exercise | A | 24.58 | 35,000 | 860,300 | 35,000 | |
Apr 11 2016 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
Page: 1